About 26 results found for searched term "NVP-2" (0.056 seconds)
Cat.No. | Name | Target |
---|---|---|
M1671 | BEZ235 | PI3K |
NVP-BEZ235, Dactolisib | ||
BEZ235 (NVP-BEZ235) is a potent dual PI3K and mTOR inhibitor of p110α, p110γ, p110δ and p110β with IC50 of 4 nM, 5 nM, 7 nM and 75 nM, respectively. | ||
M1680 | BKM120 (Buparlisib) | PI3K |
NVP-BKM120; Buparlisib | ||
BKM120 (NVP-BKM120) is a potent and highly specific oral pan-class I PI3K inhibitor. | ||
M1735 | BGT226 maleate | PI3K |
NVP-BGT226 | ||
BGT226 (NVP-BGT226) is a novel phosphoinositide 3-kinase/mTOR dual inhibitor. | ||
M1747 | LAQ824 | HDAC |
NVP-LAQ824 | ||
LAQ824 (NVP-LAQ824) is a potent novel histone deacetylase (HDAC) inhibitor with an IC50 of 0.032 μM. | ||
M1762 | Luminespib (AUY922) | HSP |
NVP-AUY922; Luminespib | ||
Luminespib (AUY922) is a small molecule Heat Shock Protein 90 (HSP90) inhibitor with IC50 values of 13 and 21 nM for HSP90α and HSP90β respectively. | ||
M1804 | NVP-BSK805 dihydrochloride | JAK |
NVP-BSK805, BSK805 2HCl | ||
NVP-BSK805 dihydrochloride is a potent and selective quinoxaline JAK2 inhibitor with IC50 values of 0.48, 0.56 and 0.58 nM for JAK2 JH1, FL JAK V617F and FL JAK2 wt respectively. | ||
M1908 | VER-82576 | HSP |
NVP-BEP800; VER82576 | ||
VER-82576 (NVP-BEP800) is a potent, orally available and selective inhibitor of Hsp90β with an IC50 of 58 nM. VER-82576 also slightly blocks Grp94 and Trap-1, with IC50s of 4.1 and 5.5 μM, respectively. | ||
M2074 | NVP-BHG712 | VEGFR/PDGFR |
NVP-BHG712 is a very potent, selective inhbitor of the receptor tyrosine kinase EphB4 (ED50 = 25 nM). | ||
M2080 | Capmatinib (INCB28060) | c-Met |
INC280; Capmatinib; NVP-INC280 | ||
Capmatinib (INCB28060) is a novel inhibitor of c-MET kinase with IC50 of 0.13 nM. | ||
M2301 | NVP-TAE226 | FAK |
TAE226 | ||
Nvp-tae 226 (TAE226) is a potent atP-competitive dual FAK and IGF-1R inhibitor with IC50 of 5.5 nM and 140 nM, respectively. Nvp-tae 226 (TAE226) also effectively inhibited Pyk2, insulin receptor (InsR), with IC50 of 3.5 nM and 40 nM. | ||
M2338 | LDE225 | Hedgehog |
Sonidegib; NVP-LDE225; Erismodegib | ||
LDE225 (NVP-LDE225; Sonidegib) is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) with IC50 of 1.3 nM (mouse) and 2.5 nM (human), respectively. | ||
M3119 | Vildagliptin | Dipeptidyl Peptidase |
LAF237; NVP-LAF 237 | ||
Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity. | ||
M3396 | NVP-BVU972 | c-Met |
NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM. | ||
M3765 | NVP-QAV-572 | PI3K |
NVP-QAV-572 is a potent PI3K kianse inhibitor with IC50 of 10 nM. | ||
M4841 | LDE225 (Sonidegib) diphosphate | Smo |
NVP-LDE225; Erismodegib; Sonidegib diphosphate | ||
LDE225 Diphosphate (Sonidegib diphosphate) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human), respectively. | ||
M7066 | NVP 231 | Others |
NVP 231 is a potent, selective and reversible CerK inhibitor. | ||
M7067 | NVP ADW 742 | IGF-1R |
ADW742; GSK 552602A; ADW | ||
Nvp-adw742 (ADW742) is an orally active, selective igF-1R tyrosine kinase inhibitor with an IC50 of 0.17 μM. Nvp-adw742 inhibited insulin receptor (InsR) with IC50 of 2.8 μM. Nvp-adw742 induces multipotent anti-proliferation/pro-apoptosis in tumor cells. | ||
M7535 | HDM201 | Mdm2 |
NVP-HDM201; Siremadlin | ||
HDM201 is a novel, highly potent and selective inhibitor of the p53-Mdm2 interaction with affinity constant for Mdm2 in the picomolar range and a selectivity ratio greater than 10000-fold vs Mdm4. | ||
M8917 | BAW2881 | VEGFR/PDGFR |
NVP-BAW2881 | ||
BAW2881 (NVP-BAW2881) is a potent and selective VEGFR2 inhibitor with activity to inhibit chronic and acute skin inflammation. | ||
M9575 | NVP-DPP-728 dihydrochloride | Dipeptidyl Peptidase |
NVP-728 2HCl | ||
NVP-DPP-728 dihydrochloride is a potent and selective dipeptidyl peptidase IV inhibitor. | ||
M10705 | NVP-2 | CDK |
NVP-2 is an effective and selective ATP competitive cyclin-dependent kinase 9 (CDK9) probe that inhibits CDK9/CycT activity.IC50 The value is 0.514 nM. NVP-2 has inhibitory effects on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases, which IC50 The values are 0.584 μM, 0.706 μM, and 0.605 μM, respectively. NVP-2 induces apoptosis. | ||
M14846 | Dactolisib Tosylate | PI3K |
BEZ235 Tosylate; NVP-BEZ 235 Tosylate | ||
Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and mTOR kinase inhibitor with IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2. | ||
M14851 | Buparlisib Hydrochloride | PI3K |
BKM120 Hydrochloride; NVP-BKM120 Hydrochloride | ||
Buparlisib Hydrochloride (BKM120 Hydrochloride) is a pan-class I PI3K inhibitor, with IC50 of 52 nM/166 nM/116 nM/262 nM for p110α/p110β/p110δ/p110γ, respectively. | ||
M14892 | NVP-BHG712 isomer | Ephrin Receptor |
NVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EPHA2 and EPHB4. | ||
M28196 | 12-Hydroxynevirapine | Metabolite/Endogenous Metabolite |
12-hydroxy-NVP; 12-OH-NVP | ||
12-Hydroxynevirapine (12-hydroxy-NVP; 12-OH-NVP) is a major oxidative metabolite of Nevirapine. Nevirapine is a non-nucleoside reverse transcriptase inhibitor indicated for the HIV-1 infections. Nevirapine causes idiosyncratic hepatotoxicity and mild-to-severe skin rashes. 12-Hydroxynevirapine, a non-reactive metabolite, can be bioactivated by sulphotransferases (SULTs) in the liver and skin, yielding the reactive species 12-Sulphoxy-nevirapine. | ||
M30890 | BGT226 | PI3K |
NVP-BGT226 | ||
BGT226 (NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ)/mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.